Guideline adherence and reasons for recommending dose reduction in a primary care-based opioid management clinic.

Background: To provide Centers for Disease Control and Prevention (CDC) guideline-recommended practices for patients on long-term opioid therapy (LTOT) including individualized decisions about opioid dose reduction, we developed the Power Over Pain (POP) Clinic.

Objective: To describe frequency and reasons for opioid dose reduction and pre-post adherence to CDC guideline-recommended practices.

Design: Retrospective chart review with qualitative and pre-post analysis.

The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.

Metastatic urothelial carcinoma (UC) carries a poor prognosis and a 5-year overall survival of less than 5%, despite standard of care therapy using cisplatin-based chemotherapy and immune checkpoint inhibitors. Thus, novel agents that improve survival and have an acceptable toxicity profile are urgently needed. Antibody-drug conjugates (ADCs) represent a promising new treatment option that utilizes the targeting ability of an antibody to deliver cytotoxic drugs directly to tumors.

Needs assessment of current palliative care education in U.S. hematology/oncology fellowship programs.

Background: Palliative care (PC) education for fellows in hematology/oncology (H/O) training programs is widely accepted, but no studies to date have assessed PC education practices and values among program leadership.

Methods: Program Directors and Associate Program Directors of active H/O fellowship programs in the U.S.

Workup of anemia in cancer.

Anemia is a common diagnosis in patients with cancer that may affect both quality of life and survival. Anemia in this patient population is often multifactorial, caused by direct effects of the malignancy, products secondary to the malignancy, the effects of treatment, or other factors. Therefore, a systematic approach is required to determine the true cause or causes of anemia.

VEGF inhibition in urothelial cancer: the past, present and future.

Purpose: To describe the role of anti-angiogenic agents that have been used as a treatment approach for locally advanced or metastatic urothelial cancers and to propose future directions.

Methods: PubMed/MEDLINE was searched for articles related to VEGF inhibition and locally advanced or metastatic urothelial cancer.

Results: Angiogenesis is a fundamental process for urothelial cancer initiation and progression.

Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.

Venetoclax (VEN) is a selective BCL-2 inhibitor that has been shown to be effective when used in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) for treatment-naïve, elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Data on its use in the relapsed/refractory setting are limited. A retrospective analysis was performed among 14 patients with relapsed or refractory AML treated with VEN combination therapy at the University of California Los Angeles from 2018-2019.

Phosphorylation of mitophagy and pexophagy receptors coordinates their interaction with Atg8 and Atg11.

The selective autophagy receptors Atg19 and Atg32 interact with two proteins of the core autophagic machinery: the scaffold protein Atg11 and the ubiquitin-like protein Atg8. We found that the Pichia pastoris pexophagy receptor, Atg30, also interacts with Atg8. Both Atg30 and Atg32 interactions are regulated by phosphorylation close to Atg8-interaction motifs.